Kornimate/medical-research-clean huggingface dataset:
the effect of no muscle relaxant versus reduced-dose rocuronium on anesthesia in adenotonsillectomy

Conditions: Muscle Relaxants

Summary: this study aimed to compare the effect of no muscle relaxants and reduced-dose rocuronium on the anesthetic induction and emergence with fentanyl in children undergoing adenotonsillectomy.

adenotonsillectomy in children is a short surgical procedure under general anesthesia. the ideal muscle relaxant requires intense neuromuscular block for optimal surgical work and complete recovery of neuromuscular function immediately after the end of the surgical procedure without postoperative morbidity. rocuronium is an intermediate acting neuromuscular blockade. reduced-dose rocuronium has been reported to provide optimal anesthetic induction without delayed recovery. the investigators aimed to compare the effect of no muscle relaxants and reduced-dose rocuronium on the anesthetic induction and emergence with fentanyl in children undergoing adenotonsillectomy. after institutional review board approval and written informed consent from the parents were obtained, 75 children (aged 3 to 10 years, asa(the american society of anesthesia ) i or ii) scheduled for adenotonsillectomy were included. anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and rocuronium 0.15 mg kg-1 (r 0.15 group) or rocuronium 0.3mg kg-1 (r 0.3 group) or saline (s group). after mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done. the investigators assessed conditions during tracheal intubation as excellent, good or poor, using five variables; jaw relaxation, vocal cord position, vocal cord movement, coughing, and movement of the limbs. the investigators added rocuronium 0.3 mg kg-1 when there was more than one poor condition. the investigators recorded the time from discontinuation of sevoflurane to time to extubation.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologist\[asa\] class 1-2 * scheduled adenotonsillectomy * written informed consent exclusion criteria: * allergy of opioids, neuromuscular blocking drugs or other medications used during general anesthesia * known or suspected upper respiratory infection * disorder affecting neuromuscular blockade * suspected difficult tracheal intubation * developmental disability * known or suspected psychologic disorder * medication (psychoactive drugs)

Keywords: no muscle relaxant rocuronium intubation condition tracheal intubation operating room time low-dose rocuronium
simulation study on advanced medical procedures under extreme environments

Conditions: Cold Exposure

Summary: background: in emergency situations in mountainous regions, medical professionals are often required to perform advanced medical procedures swiftly and efficiently. the choice of procedure and the environmental conditions can significantly impact the patient outcomes. this study seeks to evaluate the effectiveness of three advanced emergency medical procedures in a simulated scenario: orotracheal intubation with a videolaryngoscopy, minithoracotomy, and front of neck access, under both normal and cold temperature conditions. methods: on 16 and 17 october 2023, members of the medical commission of the international commission for alpine rescue performed a simulation training in an extreme environmental simulation chamber (terraxcube) in bolzano, italy. during this, each participant will perform three advanced medical procedures, once under normal environmental conditions (+20°c) and once under cold temperature conditions (-20°c), in randomized order and with a crossover design. specifically, the three advanced medical procedures consist of 1) simulation of a difficult orotracheal intubation on a dedicated mannikin with a videolaryngoscope; 2) front of neck access (fona) with the scalpel-finger-bougie technique on a dedicated mannikin model; 3) minithoracotomy and chest tube placement on a dedicated mannikin model. outcomes: primary outcome: the primary outcome is the difference in time required for three different advanced medical procedures, i.e. orotracheal intubation with a videolaryngoscopy, minithoracotomy, and front of neck access, under normal environmental conditions (+20°c) compared to cold temperature (-20°c). secondary outcomes: secondary outcomes include the success rate for three different advanced medical procedures, i.e. orotracheal intubation with a videolaryngoscopy, minithoracotomy, and front of neck access, under normal environmental conditions (+20°c) compared to cold temperature (-20°c). moreover, the subjective difficulty of performing the procedures, stress levels, emotional regualtion and decision-making process will be assessed through a questionnaire.


Eligibility criteria:
inclusion criteria: * members of the medical commission of the international commission for alpine rescue (icar) exclusion criteria: * contraindications for exposure to cold temperatures

Keywords: intubation front of neck access mini-thoracotomy cold temperature
treatment effect according to timing of administration of dwp14012 40 mg

Conditions: Erosive Esophagitis

Summary: the primary objective of this study is to establish noninferiority of efficacy of dwp14012 (40 mg once daily) based on timing of administration.

subjects will provide written informed consent for study participation and then undergo appropriate screening. subjects who meet the inclusion criteria and none of the exclusion criteria will be randomized in a 1:1 ratio to either before meal group or after meal group. subjects will be stratified into two groups according to los angeles classification grades (la grades) a/b or c/d, as determined by upper gastrointestinal (gi) endoscopy. subjects will visit the site at week 2 for endoscopic assessment. subjects whose mucosal breaks have completely healed will be prematurely withdrawn and considered to have reached end of treatment. subjects whose mucosal breaks have not healed will continue to receive ips for an additional 2 weeks and will visit the site for endoscopic assessment at week 4.

Eligibility criteria:
inclusion criteria: * adults between 19 and 75 years old based on the date of written agreement * those who have been diagnosed with erosive esophagitis of la grade a-d on the upper gastrointestinal endoscopy * those who experienced symptoms of heartburn or acid regurgitation within the last 7 days exclusion criteria: * those who have undergone gastric acid suppression or gastric, esophageal surgery * those who with clinically significant liver, kidney, nervous system, respiratory, endocrine, hematologic, cardiovascular, urinary system disease
clinical impacts of oral gastrografin follow through in adhesive small bowel obstruction (sbo)

Conditions: Small Bowel Obstruction

Summary: mini abstract : altogether 100 patients with 117 episodes of asbo were randomized into control and gastrografin groups. eight episodes in eight patients were excluded. gastrografin group showed a significant decrease of both the time between admission and operation and that of hospital stay .the need for surgery was reduced but statistically insignificant.

abstract background: many published studies have shown that gastrografin can be used for diagnosis post operative acute small bowel obstruction (asbo) and assessing the need for surgical intervention .however,the studies have reported conflicting results hence the aim of our study to test this hypothesis. patients and methods : altogether 100 patients with 117 episodes of asbo were randomized into control and gastrografin groups in a double blinded fashion. eight episodes in eight patients were excluded due to protocol violation. in gastrografin group,100 ml of the dye administered through a nasogastric tube and complete obstruction has been considered if the contrast failed to reach the colon on the 24-hour film. patients were operated on only if they developed signs of strangulation or failed to improve within 48 hours.

Eligibility criteria:
inclusion criteria: * patients admitted to our surgical department by postoperative sbo were considered for inclusion in this trial. exclusion criteria: * age less than 18 years * large bowel obstruction * recent (within 4 weeks) abdominal surgery * ileus * cancer peritonitis * peritonitis * strangulation symptoms and signs * obstructed abdominal wall or groin hernia * subtotal or total colectomy * all patients in whom the final diagnosis was not sbo

Keywords: adhesions oral contrast exploration
japanese bay88-8223 monotherapy phase ii study

Conditions: Prostatic Neoplasms

Summary: to evaluate the efficacy and safety of the best standard of care plus bay88-8223 in japanese patients with crpc and bone metastases after a multiple administration


Eligibility criteria:
inclusion criteria: * have received docetaxel or not eligible for the first course of docetaxel, i.e. patients who are not fit enough and willing. * histologically or cytologically confirmed adenocarcinoma of the prostate * multiple bone metastases * either regular (not occasional) analgesic medication use for cancer-related bone pain or treatment with external beam radiotherapy (ebrt) for bone pain. * best standard of care(bsoc) is regarded as the routine standard of care. exclusion criteria : * treatment with cytotoxic chemotherapy within previous 4 weeks, or planned during the treatment period * history of visceral metastasis, or presence of visceral metastasis

Keywords: phase ii symptomatic castration-resistant prostate cancer bone metastases
effect of neurokinin-1 receptor (nk1r) antagonism on pruritus in patients with sezary syndrome

Conditions: Sezary Syndrome; Pruritus

Summary: the purpose of this randomized, double-blinded, placebo-controlled study is to test the hypothesis that administration of aprepitant will decrease the severity of pruritus in patients with sèzary syndrome.


Eligibility criteria:
inclusion criteria: * known sezary syndrome * pruritus uncontrolled by conventional treatment. baseline visual analogue scale \> 4. * age 18 through 80 years of age. * stable medication regimens for both sezary syndrome and pruritus for 3 months prior to study participation. exclusion criteria: * known hepatic impairment (defined as liver function tests \>3 times the upper limit of normal). * pregnancy (all women of child-bearing potential will undergo urine beta-hcg testing). * concurrent use of pimozide, terfenadine, astemizole, or cisapride.

Keywords: sezary syndrome pruritus aprepitant neurokinin-1
abdominal plane blocks (apb) in chronic abdominal pain (cap)

Conditions: Abdominal Pain; Abdominal Myofascial Pain Syndrome (AMPS); Abdominal Plane Blocks (APB)

Summary: background: chronic abdominal pain (cap) is the sixth most common cause of hospital admission from any cause in women and the tenth most common cause in men. in the uk, it has been estimated that chronic abdominal pain costs the economy in excess of £100 million per annum. the mechanism of cap is poorly understood. patients with acute exacerbation of their cap have multiple hospital admissions, prolonged length of stay and utilise significant health care resources. these patients have undergone multiple investigations with negative results leading to frustration for both the patient and the clinician. additional testing and investigations increases costs, patient morbidity and comes with added risks. patients are discharged once the flare up settles. the investigators have shown that treating patients with steroid injection followed by pulsed radio frequency treatment six months later can reduce the length of stay, repeat hospital admission, improve mood and provide durable pain relief in patients with cap. the steroid is injected into a specific plane in the abdominal wall and is called abdominal plane block (apb). the investigators currently offer abp treatment as a standard treatment in the management of patients with cap. aim of the study is to evaluate the effectiveness of abdominal plane block (apb) treatment in reducing hospital readmission over 12 months in patients admitted with exacerbation of cap methods: the proposed study is a prospective, observational pilot study that will be conducted at leicester general hospital over 36 months. after providing written consent, adult patients admitted to the hospital with acute exacerbation of cap will receive two sequential apb treatments (steroid injection followed by pulsed radio frequency treatment) six month apart. if the first treatment with steroid does not provide any benefit, the participants will receive a rescue treatment (trigger point injection with steroids). participants will be asked to complete questionnaires on pain scores, mood and quality of life. length of hospital stay, number of hospital re-admission following apb treatment as well as any complication from the apb treatment will be recorded. participation in the study will end at 12 months following the first apb treatment on completion of relevant questionnaires.


Eligibility criteria:
inclusion criteria: 1. all patients aged over 18 years. 2. chronic abdominal pain for above 6 months 3. moderate to severe pain in the abdomen: baseline nrs \>4 (worst pain the last 24 hours) exclusion criteria: 1. lack of consent, including from those patients who lack mental capacity to give informed consent. 2. patients with known history of drug allergy to depomedrone 3. patients with infection at injection site at on day of treatment.
effects of fatty and lean fish intake on cardiovascular risk factors in subjects with coronary heart disease

Conditions: Blood Pressure; Arrhythmia; Inflammation

Summary: the aim of the study is to examine the effects of fatty fish and white (lean) fish on cardiovascular disease risk factor levels in subjects with established coronary heart disease using multiple medications. the main end points are blood pressure, serum lipids, inflammatory markers, arrhythmias and gene expression in peripheral mononuclear cells. the study design was a controlled, parallel study lasting 8 weeks with three diet groups: fatty fish, white fish and control group (lean pork, beef or chicken).


Eligibility criteria:
inclusion criteria: * myocardial infarction or unstable ischemic attack * use of beta blockers * normal sinus rhythm * fasting serum triglyceride less or equal to 3.5 mmol/l * fasting serum cholesterol less or equal to 8 mmol/l * bmi 18.5-30 kg/m2 * fasting plasma glucose less or equal to 7 mmol/l exclusion criteria: * diabetes * use of other antiarrhythmic medications than beta blockers * atrial fibrillation * use of psychotropic medications * abnormal liver, thyroid or kidney function * inflammatory bowel disease * excessive use of alcohol * use of fish oil supplements or high habitual intake of fish

Keywords: coronary heart disease
effect of sevelamer on glucose tolerance and insulin sensitivity in patients with chronic renal failure (ckd)

Conditions: Kidney Failure, Chronic; End-Stage Renal Disease; Insulin Resistance; Hyperphosphatemia

Summary: the purpose of this study is to perform a randomized, controlled clinical trial to investigate if the phosphate binder sevelamer can improve insulin resistance and glucose handling in patients receiving maintenance hemodialysis.


Eligibility criteria:
inclusion criteria: * male or female patients 18-80 years of age with chronic renal failure treated with maintenance hd for \>3 months. exclusion criteria: * diabetes mellitus * treatment with sevelamer within 3 months prior to enrollment * acute, clinically significant inflammation within 1 month prior to enrollment * pregnancy or breast-feeding * clinically significant obstipation or bowel obstruction * discontinuation of previous sevelamer treatment because of side effects * expected time in hd \< 1 year * unwillingness to undergo the investigations and follow-up required in the the protocol * patients who have received any investigational drug within 1 month prior to enrolment * participation in another study, which may interfere with the present study

Keywords: chronic kidney disease end-stage renal disease phosphate binder insulin resistance glucose intolerance sevelamer
post marketing surveillance study in patients with idiopathic parkinson's disease

Conditions: Parkinson Disease

Summary: documentation of the effect of an direct or overlapping switch from another dopamine agonist to sifrol® on motor function, psychopathological disturbances and mood, assessment of the reasons for the switch and the reasons for using sifrol®, equivalent doses at the end of the switch and tolerability of sifrol® in ambulatory patients suffering from idiopathic parkinson's disease under routine conditions


Eligibility criteria:
inclusion criteria: * patients with idiopathic parkinson's disease who are planned to undergo a switch from another dopamine agonist to sifrol® exclusion criteria: * neurologists and psychiatrists are asked to consider the summary of product characteristics (spc) for sifrol®
evaluation of the role of adalimumab on extraarticular manifestation - bone metabolism and bone mineral density in patients with active rheumatoid arthritis

Conditions: Rheumatoid Arthritis; Osteoporosis

Summary: this post marketing observational study will be conducted in a prospective, single country, multicenter format to assess the prevention of generalized bone loss in patients with active rheumatoid arthritis (ra) treated with adalimumab (humira®) in pragmatic prescribing situations. the investigational sites will be centers with experience in the treatment of ra patients and anti-tumor necrosis factor-alpha (tnf-a) therapy. the investigators will be rheumatologists authorized by the czech rheumatologic society for prescribing biological treatment.


Eligibility criteria:
inclusion criteria: * patients with active early and long-standing ra according to american college of rheumatology (acr) 1987 revised criteria. * patients with high disease activity das28 ≥ 5.1 according to the czech rheumatological society criteria. * patients must fulfill national guidelines for use of anti-tnf: inadequate clinical response to at least one disease-modifying antirheumatic drug (dmard; methotrexate, sulphasalazine, leflunomide, hydroxychloroquine, or combinations) and oral glucocorticoids (equivalent to ≥ 5 mg prednisolone per day), (for romania except glucocorticoids); chest x-ray, purified protein derivative (ppd)-skin test, quantiferon/tuberculosis (tb) gold test (if available) negative for tb. exclusion criteria: * patients who have had a history of tnf blocking or rituximab therapy. * patients who are being treated or will be treated with drug at risk of interaction with adalimumab (humira). * pregnant females and/or females without adequate method of contraception. * patients who didn't receive prior dmard therapy. * patients participating in another study or clinical trial. * patients with severe osteoporosis (t-score \[number that indicates whether or not bone loss has occurred\] of ≤ -2.5 and/or prior vertebral fracture/s). * patients with a history of total hip replacement of both extremities. * patients who currently receive and/or received bone metabolism modulating agents including selective estrogen receptor modulators (serms), bisphosphonates, parathyroid hormone or anti-receptor activator of nuclear factor-kappab ligand (rankl) therapy. * subjects who are not eligible for tnf-blocking therapy according to the czech national registry (attra).

Keywords: bone mineral density bone turnover markers rheumatoid arthritis osteoporosis
bendamustine hydrochloride injection for previously untreated chronic lymphocytic leukemia

Conditions: Chronic Lymphocytic Leukemia; Leukemia; Neoplasms

Summary: the purpose of this study is to determine whether bendamustine is effective in the treatment of initial treatment of chronic lymphocytic leukemia (cll).


Eligibility criteria:
inclusion criteria: * patients must have a diagnosis of cll; * no prior or no standard treatment for cll; * binet stage b, c or symptomatic stage a; * needs treatment to control diseases; * (eastern cooperative oncology group)ecog performance status ≤ 2 * life expectancy ≥3 months * written informed consent exclusion criteria: * patients were diagnosed with or treated for malignant tumors other than cll (including active central nervous system lymphoma) within one year prior to entering the study * transformation to richter's syndrome, or prolymphocytic leukemia(pll) * autoimmune hemolytic anemia requiring glucocorticoid therapy * autoimmune thrombocytopenia requiring glucocorticoid therapy * alanine aminotransferase(alt)\>3 times upper limits of normal value, aspartate aminotransferase(ast)\>3 times upper limits of normal value, total bilirubin(tbil)\>2 times upper limits of normal value, serum creatinine\>1.5 times upper limits of normal value; * other serious concomitant diseases which affect participation of this study(uncontrolled diabetes, gastric ulcer, cardiac and pulmonary diseases, at active phases of autoimmune diseases; * serious or uncontrolled infections; * central nervous system dysfunction with clinical symptoms; * patients received major surgery within 30 days prior to study entry; * pregnant or lactating women * allergic to study drug or mannitol * participation in any other clinical trials within 3 months prior to study entry
artificial intelligence-assisted colonoscopy on detection of missed proximal lesions

Conditions: Colon Adenoma; Colon Polyp

Summary: this is a prospective multi-center randomized study is to determine whether the use of artificial intelligence (ai)-assistance could reduce the miss rates of polyps and adenomas in the proximal colon during tandem examination

centers 1. queen mary hospital, hong kong, china (co-ordinating center) 2. tan tock seng hospital, singapore, singapore 3. institute of gastroenterology and hepatology, vietnam union of science and technology association, hanoi, vietnam study population inclusion: all adult patients, aged 40 or above, undergoing outpatient colonoscopy in the participating centers will be recruited. exclusion: * history of inflammatory bowel disease * history of colorectal cancer * previous bowel resection (apart from appendectomy) * peutz-jeghers syndrome, familial adenomatous polyposis or other polyposis syndromes * bleeding tendency or severe comorbid illnesses for which polypectomy is considered unsafe. post-randomization exclusion: * cecum could not be intubated for various reasons * boston bowel preparation scale (bbps) score of the proximal colon is \<2 study design this is a prospective randomized trial comparing the miss rates of proximal colonic lesions by ai assisted colonoscopy or conventional colonoscopy (fig. 1). the study will be conducted in the endoscopy centre of the participating hospitals. randomization eligible patients in each center will be randomly allocated in a 1:1 ratio to undergo tandem colonoscopy of the proximal colon first with ai-assistance and follow by conventional white light colonoscopy (group 1) or conventional white light colonoscopy without ai assistance follow by conventional colonoscopy (group 2). proximal colon refers to colonic segment proximal to the splenic flexure. randomization will be conducted in blocks of 4 by computer generated random sequences and stratified according to indications of colonoscopy (symptomatic vs screening/surveillance). patients will be blinded to the group assignment.

Eligibility criteria:
inclusion criteria: * all adult patients, aged 40 or above, undergoing outpatient colonoscopy in the participating centers will be recruited exclusion criteria: * history of inflammatory bowel disease * history of colorectal cancer * previous bowel resection (apart from appendectomy) * peutz-jeghers syndrome, familial adenomatous polyposis or other polyposis syndromes * bleeding tendency or severe comorbid illnesses for which polypectomy is considered unsafe.

Keywords: colonoscopy artificial intelligence